ESOMEPRAZOLE MAGNESIUM Drug Patent Profile

When do Esomeprazole Magnesium patents expire, and when can generic versions of Esomeprazole Magnesium launch?

Esomeprazole Magnesium is a drug marketed by Alkem Labs Ltd, Amneal Pharms Ny, Aurobindo Pharma Ltd, Cipla, Cisen, Cspc Ouyi, Dr Reddys, Ethypharm, Glenmark Speclt, Granules, Graviti Pharms, Guangzhou Novaken, Hec Pharm, Hetero Labs Ltd Iii, Indchemie Health, Lannett Co Inc, Macleods Pharms Ltd, Mylan, Prinston Inc, Sun Pharm, Torrent, Zhejiang Yongtai, Zydus Pharms, Aurobindo Pharma, Guardian Drug, Marksans Pharma, Perrigo R And D, Pharmobedient, P And L, and Dexcel. and is included in fifty NDAs. There are two patents protecting this drug.

This drug has four patent family members in three countries.

The generic ingredient in ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium. There are seventy-four drug master file entries for this compound. One hundred and eleven suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esomeprazole Magnesium

A generic version of ESOMEPRAZOLE MAGNESIUM was approved as esomeprazole magnesium by MYLAN on August 2^nd, 2015.

Summary for ESOMEPRAZOLE MAGNESIUM

International Patents:	4
US Patents:	2
Applicants:	30
NDAs:	50
Finished Product Suppliers / Packagers:	109
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	24
Patent Applications:	1,905
Drug Prices:	Drug price information for ESOMEPRAZOLE MAGNESIUM
Drug Sales Revenues:	Drug sales revenues for ESOMEPRAZOLE MAGNESIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESOMEPRAZOLE MAGNESIUM
What excipients (inactive ingredients) are in ESOMEPRAZOLE MAGNESIUM?	ESOMEPRAZOLE MAGNESIUM excipients list
DailyMed Link:	ESOMEPRAZOLE MAGNESIUM at DailyMed

See drug prices for ESOMEPRAZOLE MAGNESIUM

See drug sales revenues for ESOMEPRAZOLE MAGNESIUM

Recent Clinical Trials for ESOMEPRAZOLE MAGNESIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Sinorda Biomedicine Co., Ltd	PHASE1
Livzon Pharmaceutical Group Inc.	PHASE3
Bio-innova Co., Ltd	PHASE1

See all ESOMEPRAZOLE MAGNESIUM clinical trials

Pharmacology for ESOMEPRAZOLE MAGNESIUM

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ESOMEPRAZOLE MAGNESIUM

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for ESOMEPRAZOLE MAGNESIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	2.5 mg and 5 mg	021957	1	2018-09-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	10 mg	022101	1	2018-07-06
NEXIUM 24HR	Delayed-release Capsules	esomeprazole magnesium	20 mg	204655		2014-04-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	20 mg and 40 mg	021957	1	2013-08-01
NEXIUM	Delayed-release Capsules	esomeprazole magnesium	20 mg and 40 mg	021153	1	2005-08-05

US Patents and Regulatory Information for ESOMEPRAZOLE MAGNESIUM

ESOMEPRAZOLE MAGNESIUM is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	212651-002	Mar 5, 2025	AB	RX	No	No
Sun Pharm	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	209735-001	Apr 30, 2018	AB	RX	No	No
Indchemie Health	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	210559-002	Feb 26, 2021	AB	RX	No	No
Amneal Pharms Ny	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	209716-001	Jun 5, 2019		DISCN	No	No
Pharmobedient	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	212376-001	Oct 16, 2019		DISCN	No	No
Zhejiang Yongtai	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	217022-001	Dec 27, 2023	AB	RX	No	No
Aurobindo Pharma	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	209339-001	Oct 16, 2017		OTC	No	No

International Patents for ESOMEPRAZOLE MAGNESIUM

See the table below for patents covering ESOMEPRAZOLE MAGNESIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
European Patent Office	3471708	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
World Intellectual Property Organization (WIPO)	2017216789
Australia	2017285390
European Patent Office	3471708
European Patent Office	3932396

Supplementary Protection Certificates for ESOMEPRAZOLE MAGNESIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214

ESOMEPRAZOLE MAGNESIUM: Market dynamics and financial trajectory by channel, pricing, and exclusivity risk

Last updated: June 24, 2026

Esomeprazole magnesium is a generic-dominant proton-pump inhibitor (PPI) market in the US and most major geographies. The financial trajectory is shaped less by patent leverage today and more by (1) post-generic price erosion, (2) conversion from branded to generic substitution, (3) channel mix (retail vs mail vs hospital), (4) reimbursement pressure, and (5) residual value in specific presentations (40 mg/20 mg oral solids; selected IV products in some markets). In the US, the product category is largely “mature generic,” so profitability is driven by scale manufacturing, contracting, and inventory discipline rather than by differentiated clinical IP.

---

What is the current market size and growth profile for esomeprazole magnesium (PPI) by geography?

Where does revenue pool: US vs EU5 vs UK vs emerging markets?

Esomeprazole magnesium sits inside the broader esomeprazole (and PPI) therapeutic class, where growth is muted by:

• Mature diagnosis and maintenance use patterns.
• High generic penetration.
• Frequent payer restrictions and formulary tiering that compress net prices.
• Step-down prescribing norms for long-term GERD/erosive esophagitis.

Revenue trajectory pattern (typical for mature generic PPIs):

• Unit growth modest (population growth and dosing persistence).
• Value growth near zero to low single digits driven by brand-to-generic conversion having largely completed.
• Seasonality and churn from pharmacy switching and contract renewals.
• Price volatility tied to tender outcomes, wholesaler inventory turns, and parallel trade in some geographies.

Featured snippet answer

Esomeprazole magnesium revenue behaves like a mature generic PPI: units hold up better than dollars, and net sales are more sensitive to contracting and reimbursement than to new patient acquisition.

---

How has pricing and reimbursement evolved for generic esomeprazole products?

Why net prices keep falling after generic entry

Generic PPIs often experience rapid post-launch price compression because:

• Multiple generic manufacturers compete simultaneously at entry.
• Payers prefer least-cost alternatives within therapeutic drug classes.
• PBM and wholesaler rebates or fees drive net-to-gross compression.
• Wholesale acquisition cost (WAC) does not track net pricing due to channel negotiations.

Key pricing drivers

• Formulation and strength: 20 mg vs 40 mg economics can diverge depending on demand mix.
• Packaging: bottle size and unit count affect pharmacy dispensing economics.
• Channel: hospital pharmacy procurement can price differently than retail.
• Switching: formulary switching rules influence volume capture for new entrants.
• Parallel import dynamics (outside US): can pressure local pricing and create discontinuities in supply.

---

What are the main market dynamics affecting esomeprazole magnesium demand?

Payer formulary positioning for PPIs

PPIs remain standard of care for GERD, erosive esophagitis, and ulcer indications. Demand is structurally stable but economically contested:

• Formulary tiering tends to cluster all PPIs into a preferred list and one or more preferred generic SKUs.
• Step edits and prior authorization are more common for higher-cost alternatives, but esomeprazole magnesium typically sits in the generic-preferred zone once multiple competitors exist.

Clinical and utilization factors

• Long-term safety monitoring requirements shape physician behavior but do not eliminate PPI use.
• Step-down and intermittent strategies can reduce daily DDD consumption in some cohorts.
• Indication expansion is limited because esomeprazole is already widely covered.

---

How does the product’s financial trajectory differ between oral solids and other presentations?

Oral tablets/capsules: the volume engine

Oral esomeprazole magnesium is usually the dominant revenue contributor for generic PPIs:

• Broad retail coverage
• High prescriber familiarity
• Multiple strength availability supporting dosing flexibility

Injectables (where marketed): limited upside, procurement-driven

Where IV esomeprazole exists (market dependent), it tends to be:

• Hospital procurement-led
• Sensitive to tender pricing and supply continuity
• Less price elastic than oral at the hospital level, but still compressed by multi-source procurement

---

How do exclusivity and patent cliffs affect the revenue outlook for esomeprazole magnesium today?

Exclusivity status: why the current model is “generic steady-state”

In mature PPIs, the financial narrative typically transitions from:

• Branded volume growth (pre-generic) to
• Post-generic margin compression (multi-source competition) to
• Contracted stability (least-cost leadership and high-volume manufacturing)

For esomeprazole magnesium, the market is already in the post-cliff regime in most developed markets.

Implication for investors and business development

• Revenue upside is capped unless a manufacturer wins share through contracting scale or supply reliability.
• New entries create margin pressure more than incremental value.
• “Differentiated value” comes from logistics, cost-per-unit manufacture, and tender execution rather than from novel clinical IP.

---

What generic entry risks exist for esomeprazole magnesium (Paragraph IV, settlement, biosimilar risk)?

Paragraph IV and Hatch-Wax relevance

Paragraph IV litigation is usually a pre-generic entry or early generic switching event. In a mature molecule like esomeprazole, the most common scenario is:

• No active branded exclusivity to attack
• Multi-generic landscape already established
• Market share determined by contracting and supply economics

Biosimilar risk

Esomeprazole magnesium is a small-molecule drug, so biosimilar risk is not applicable.

---

What is the patent estate strength for esomeprazole magnesium and does it still matter commercially?

Commercial relevance

In most developed markets, generic esomeprazole is already widely available, so:

• Broad molecule-level patent coverage does not constrain day-to-day competition.
• Remaining patent tail (if any) is usually formulation- or method-specific and has limited effect on the dominant oral solid revenue streams.

Business implication

The practical “IP strength” for esomeprazole magnesium is mostly about:

• Whether any late-expiring formulation or method patents still restrict certain dosage forms or routes.
• Whether regulatory exclusivities exist for specific ANDA references (less common in mature PPIs).

---

How many competitors typically operate in esomeprazole magnesium and what does that do to margins?

Market structure

Mature generic PPIs usually run:

• High number of ANDA/marketed generic SKUs
• Multiple manufacturers per strength and pack size
• Frequent price competition

Margin mechanics

• Gross margin pressure increases with each additional active supplier.
• Net margin depends on rebates, distribution fees, contracting terms, and manufacturing cost curve.
• The winners are typically those with:
  • Largest volume plants
  • Lowest unit manufacturing costs
  • Strong forecasting and inventory management
  • Ability to offer contract pricing reliably

---

What does the competitive landscape look like for esomeprazole magnesium in the US?

Generic substitution and pharmacy economics

In the US retail channel:

• Pharmacy systems favor least-cost alternatives.
• Higher WAC SKUs are not necessarily higher net price.
• Switching happens quickly once a new competitor is on formulary or captured by PBM logic.

Hospital and IDN procurement

In hospitals:

• Supply continuity matters as much as price.
• Contracts can lock in a preferred supplier for a procurement cycle.
• Tender wins shift volume rapidly and can create short-term discontinuities in revenue for weaker suppliers.

---

How does esomeprazole magnesium compare with other PPIs (omeprazole, pantoprazole, lansoprazole) on economics and risk?

Relative market dynamics

PPIs share the same macro drivers:

• Generic penetration
• PBM tiering
• Tender contracting

The relative differentiators are mostly:

• Therapeutic preference tied to formulary history
• Specific strengths and pack sizes demanded
• Manufacturing cost efficiency

Business take

Esomeprazole magnesium is less exposed to “class disruption” than to ongoing price compression. The main competitive risk is not a therapy shift but a continued least-cost replacement inside the class.

---

What FDA and Orange Book status matters for esomeprazole magnesium?

Regulatory framing

For a mature generic molecule, the decision logic typically revolves around:

• Whether the reference listed drug and listed patents still exist for specific dosage forms.
• Whether any exclusivity remains tied to the RLD.
• Whether any specific generic entrant has regulatory or litigation constraints.

Featured snippet answer

Regulatory risk in mature esomeprazole is primarily about which competitors are already cleared and contracted, not about a single upcoming regulatory event.

---

What are the expected financial outcomes for manufacturers holding esomeprazole magnesium lines?

Base-case financial trajectory (typical mature generic model)

• Revenue: modest growth or flat, largely tied to share and contracting.
• Gross margin: pressured by price competition.
• EBITDA: supported by cost-down initiatives, plant utilization, and supply chain efficiency.
• Working capital: can swing with inventory turns if channel inventory behavior changes.

Upside and downside

• Upside: tender win cycles, reduced competitive entry, or manufacturing cost advantage.
• Downside: price undercutting by new suppliers, supply interruptions, higher raw-material or packaging costs, and loss of preferred-contract status.

---

Key Takeaways

• Esomeprazole magnesium revenue behaves like a mature generic PPI market: unit stability with dollar compression driven by contracting and reimbursement.
• The financial trajectory is dominated by price erosion and channel mix rather than by patent-driven milestones.
• Competitive advantage comes from manufacturing cost and supply reliability, not differentiation in clinical IP.
• The main threat is continued least-cost replacement inside the PPI class as additional generic volume concentrates among best-priced suppliers.

---

FAQs

1) Does esomeprazole magnesium have higher pricing power than omeprazole or pantoprazole generics?

No. In mature markets, all PPIs face similar formulary and least-cost pressures; pricing power mainly reflects which SKU wins contracts and distribution.

2) What drives quarterly revenue volatility for generic esomeprazole manufacturers?

Tender cycles, wholesaler inventory rebalancing, and pharmacy/PBM switching speed after new SKU additions.

3) Are there formulation-specific opportunities for esomeprazole magnesium beyond standard oral tablets?

Opportunities tend to be limited and must be validated against regulatory status and existing multi-source competition for any non-standard presentation.

4) How does supply risk affect net sales in the esomeprazole magnesium market?

Stock-outs can convert revenue quickly to rival suppliers in retail and hospital channels where substitution is permitted, creating gap revenue and long recovery.

5) Is litigation a meaningful driver of market share for esomeprazole magnesium today?

For most developed markets, litigation is usually not the dominant driver in a fully genericized molecule; contracting and cost leadership drive share.

---

References

No sources were provided in the prompt and no verifiable, molecule-specific financial metrics, patent dates, Orange Book listings, or competitor sales figures are included here.